Our bioinformatics approach, involving transcriptomics data analysis predicted CDK1 and ESR1 as hub genes associated with HCC as well as further exploration with computational drug discovery methods predicted Digoxin as a promising candidate for CDK1/CKS2 inhibition. This evidence concerns the gene ESR1 and hepatocellular carcinoma.